Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Bryce AH, et al. Among authors: phung d. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227. doi: 10.1038/pcan.2016.71. Epub 2017 Jan 24. Prostate Cancer Prostatic Dis. 2017. PMID: 28117385 Free PMC article.
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Armstrong AJ, Saad F, Phung D, Dmuchowski C, Shore ND, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J. Armstrong AJ, et al. Among authors: phung d. Cancer. 2017 Jun 15;123(12):2303-2311. doi: 10.1002/cncr.30587. Epub 2017 Feb 7. Cancer. 2017. PMID: 28171710 Free PMC article. Clinical Trial.
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung D, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Alumkal JJ, et al. Among authors: phung d. Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3. Clin Genitourin Cancer. 2017. PMID: 28344102 Clinical Trial.
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.
Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Devlin N, et al. Among authors: phung d. Health Qual Life Outcomes. 2017 Jun 23;15(1):130. doi: 10.1186/s12955-017-0704-y. Health Qual Life Outcomes. 2017. PMID: 28645287 Free PMC article. Clinical Trial.
The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
Beer TM, Miller K, Tombal B, Cella D, Phung D, Holmstrom S, Ivanescu C, Skaltsa K, Naidoo S. Beer TM, et al. Among authors: phung d. Eur J Cancer. 2017 Dec;87:21-29. doi: 10.1016/j.ejca.2017.09.035. Epub 2017 Oct 31. Eur J Cancer. 2017. PMID: 29096157 Clinical Trial.
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Hussain M, et al. Among authors: phung d. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. N Engl J Med. 2018. PMID: 29949494 Free PMC article. Clinical Trial.
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung D, Parli T, Krivoshik A, Beer TM. Armstrong AJ, et al. Among authors: phung d. Eur Urol Oncol. 2019 Nov;2(6):677-684. doi: 10.1016/j.euo.2018.11.005. Epub 2018 Dec 3. Eur Urol Oncol. 2019. PMID: 31274110 Free article. Clinical Trial.
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Graff JN, et al. Among authors: phung d. Ann Oncol. 2016 Feb;27(2):286-94. doi: 10.1093/annonc/mdv542. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578735 Free article. Clinical Trial.
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials.
Saad F, Ivanescu C, Phung D, Loriot Y, Abhyankar S, Beer TM, Tombal B, Holmstrom S. Saad F, et al. Among authors: phung d. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):110-116. doi: 10.1038/pcan.2016.62. Epub 2017 Jan 3. Prostate Cancer Prostatic Dis. 2017. PMID: 28045115 Free PMC article.
266 results